Aveo Oncology Inc. signed up specialty cancer firm Eusa Pharma Ltd. as its European partner for its VEGF tyrosine kinase inhibitor, tivozanib, in a deal that helps validate the biotech’s continued push for the beleaguered cancer drug, which might finally be approaching the finish line, at least in Europe.